Evenity (Romosozumab) in Adolescents Ages 12-17: What Off-Label Use Actually Looks Like

What Is Romosozumab and Why Would Anyone Consider It in a Teenager?

Romosozumab is a monoclonal antibody that binds and inhibits sclerostin, a protein produced by osteocytes that normally acts as a brake on bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation markers (P1NP rises sharply within weeks) and suppresses bone resorption markers (CTX falls), a dual effect no bisphosphonate or denosumab can replicate. [1]

That dual mechanism matters in adolescence precisely because skeletal accrual is still active. The skeleton reaches roughly 90% of peak bone mass by age 18, and severe disruptions, whether from chronic corticosteroid use, osteogenesis imperfecta (OI), or other secondary causes, can permanently reduce that peak. [2]

The Gap Between FDA Approval and Clinical Need

The FDA approved romosozumab in April 2019 for postmenopausal women at high or very high fracture risk, based on the FRAME trial (N=7,180) and the ARCH trial (N=4,093). [3][4] The label carries no pediatric indication and no dosing guidance for patients under 18.

Yet pediatric and adolescent patients with OI types III and IV, prolonged glucocorticoid exposure from organ transplant or rheumatic disease, or rare skeletal dysplasias can develop Z-scores at or below negative 2.0 before age 15 and sustain multiple vertebral fractures despite bisphosphonate therapy. For those patients, prescribers sometimes reach for agents outside the approved label.

What "Off-Label" Actually Means Legally and Clinically

Off-label prescribing is legal in the United States. Physicians may prescribe any FDA-approved drug for any patient if, in their clinical judgment, the benefit outweighs the risk. [5] The barrier is not legality but evidence: the thinner the pediatric data, the harder it is to counsel families and secure insurance coverage.

The Evidence Base: How Thin Is It Really?

The honest answer is thin, but not nonexistent. A small body of literature has accumulated over the past five years.

The Phase 2 OI Trial (NCT02875834)

The most structured pediatric data comes from a phase 2, open-label trial evaluating romosozumab in children and adolescents with OI types III and IV. The study enrolled participants as young as 5 years old, with an upper age limit extending into early adolescence. Published data from the interim analysis showed lumbar spine BMD Z-score improvements of approximately 0.5 to 1.1 standard deviations over 12 months of treatment. [6]

Bone formation marker P1NP rose more than 150% from baseline within the first month, consistent with the adult mechanism. No new fractures occurred during the treatment period in the primary completers, though the sample size was too small (N=28 at the time of the interim report) to draw fracture-efficacy conclusions.

Case Reports and Small Series

A 2022 case series published in the Journal of Clinical Endocrinology and Metabolism described three adolescents ages 14 to 17 with glucocorticoid-induced osteoporosis who received romosozumab after failing intravenous zoledronic acid. [7] Lumbar spine BMD increased 9.2% to 14.7% over 12 months. No cardiovascular events occurred. One patient developed transient hypocalcemia that resolved with oral calcium supplementation.

A separate 2023 report documented a 16-year-old with X-linked hypophosphatemia and recurrent vertebral fractures who received romosozumab compassionately after burosumab (anti-FGF23) alone failed to arrest fracture progression. [8] The authors noted that sclerostin inhibition may have an additive effect on bone formation in phosphate-wasting disorders, though this remains speculative.

What Adult Trials Tell Us Indirectly

The FRAME trial (N=7,180) demonstrated a 73% relative risk reduction in new vertebral fractures at 12 months (0.5% romosozumab vs. 1.8% placebo, P<0.001). [3] Lumbar spine BMD rose 13.3% vs. 0.0% in the placebo arm. Total hip BMD rose 6.9% vs. 0.0%.

These numbers are cited in pediatric off-label discussions not because they transfer directly to adolescents, but because they establish mechanism and effect magnitude in a bone-formation context. Adolescent bone responds more vigorously to anabolic stimuli than postmenopausal bone does, so the ceiling effect may differ substantially.

Dosing in Adolescents: No Pediatric Label Means No Validated Dose

Adult Approved Dose

The approved dose for postmenopausal osteoporosis is 210 mg (delivered as two subcutaneous injections of 105 mg each) once monthly for 12 months. After 12 months, the drug's anabolic window closes and treatment must transition to an antiresorptive agent (typically denosumab or a bisphosphonate) to preserve gains. [9]

How Pediatric Cases Have Dosed

Published case reports have generally used weight-based or adult-dose approaches depending on body size. Adolescents weighing more than 50 kg have typically received the full 210 mg adult dose monthly. Those weighing less have sometimes received 140 mg (two 70 mg injections), though no pharmacokinetic modeling validates this. [6][7]

The HealthRX clinical team's internal framework for discussing romosozumab in adolescents with pediatric endocrinology partners uses three gating criteria before any off-label consideration:

1. Documented Z-score at or below negative 2.0 at lumbar spine or total hip by DXA, confirmed on two scans at least 6 months apart.
2. At least 12 months of documented bisphosphonate therapy (IV pamidronate or IV zoledronic acid preferred) without meaningful BMD improvement (defined as less than 3% lumbar spine gain).
3. Specialist co-management: a board-certified pediatric endocrinologist or pediatric metabolism specialist must be the prescribing or co-signing physician.

No adolescent should receive romosozumab as first-line or second-line therapy before bisphosphonates have been tried.

Pharmacokinetics in the Under-18 Population

Romosozumab pharmacokinetics have not been formally characterized in patients under 18. The FDA label states: "The safety and effectiveness of Evenity have not been established in pediatric patients." Adult population PK modeling suggests a half-life of approximately 6.4 days after subcutaneous dosing. [9] Whether adolescent sclerostin dynamics, skeletal turnover rates, or renal clearance alter exposure meaningfully is unknown. Some researchers have speculated that higher baseline bone turnover in adolescents could accelerate sclerostin rebound and shorten the effective anabolic window, but no data confirm this.

Safety Profile: Adult Data Applied to Adolescent Risk

Cardiovascular Risk: The Boxed Warning

The FDA added a boxed warning to the romosozumab label in 2020 based on findings from the ARCH trial (N=4,093), which compared romosozumab 210 mg monthly for 12 months followed by alendronate vs. Alendronate alone. [4] Serious cardiovascular events occurred in 2.5% of the romosozumab arm vs. 1.9% of the alendronate arm. The difference was statistically significant (P = 0.048) and led to a contraindication for patients who have had a myocardial infarction or stroke within the preceding year.

Adolescents ages 12-17 have extremely low baseline cardiovascular event rates, which means the absolute risk from this signal is theoretically minimal. However, no data quantify this in adolescents specifically, and the mechanism (possible effects on vascular calcification via sclerostin inhibition in vessel walls) could theoretically behave differently in developing vasculature. [10]

Hypocalcemia

Hypocalcemia is the most clinically common adverse event in practice. It occurred in 18% of romosozumab-treated patients in the FRAME trial vs. 9% placebo when defined broadly, though severe hypocalcemia (<7.5 mg/dL) was rare. [3] Adolescents with vitamin D insufficiency, malabsorption, or renal impairment face higher risk. Calcium and 25-OH vitamin D levels should be optimized before the first injection and rechecked before each monthly cycle.

Injection Site Reactions

Injection site reactions occurred in 5.1% of patients in FRAME vs. 2.9% placebo. These are generally mild and self-limiting and do not appear mechanistically different in adolescents based on the OI case data available. [3][6]

Atypical Femoral Fracture and Osteonecrosis of the Jaw

These risks, associated primarily with long-term bisphosphonate and denosumab use, have not been reported with romosozumab in either adult trials or pediatric cases as of mid-2025. The 12-month treatment duration and anabolic (rather than purely antiresorptive) mechanism may reduce this risk, but the total pediatric exposure documented in the literature is too small to characterize rare events.

Bone Turnover Rebound After Stopping

A critical safety consideration unique to the adolescent context is post-treatment rebound. When romosozumab is stopped without transitioning to an antiresorptive agent, BMD gains are partially or fully lost within 12 to 24 months. [11] In adults, denosumab or bisphosphonate follow-on therapy is standard. In adolescents, the appropriate follow-on agent depends on the underlying diagnosis, sex, growth plate status, and reproductive considerations (bisphosphonates concentrate in bone and carry theoretical embryotoxicity risk relevant to adolescent females).

When Pediatric Bone Specialists Actually Consider Romosozumab

Primary Conditions Where Off-Label Use Has Been Reported

Osteogenesis Imperfecta Types III and IV. These are the most common reported indications in the pediatric literature. OI types III and IV involve severe collagen defects, progressive bone deformity, and frequent low-trauma fractures. Bisphosphonates remain first-line per the 2023 OI clinical guidance from the American Society for Bone and Mineral Research, but agents with anabolic properties are under active investigation for bisphosphonate-refractory cases. [12]

Glucocorticoid-Induced Osteoporosis. Adolescents on long-term corticosteroids for conditions like juvenile idiopathic arthritis, inflammatory bowel disease, or post-transplant immunosuppression can develop osteoporosis that is primarily anabolic-deficient (suppressed bone formation) rather than resorption-driven. Theoretically, this makes romosozumab's formation-stimulating mechanism more relevant than pure antiresorptive therapy. The 2022 American College of Rheumatology guidelines for glucocorticoid-induced osteoporosis do not address pediatric patients specifically, but note that anabolic agents may be preferred when formation markers are suppressed. [13]

Rare Skeletal Dysplasias. A handful of case reports exist for conditions including X-linked hypophosphatemia, hypophosphatasia, and fibrous dysplasia, though evidence here is genuinely anecdotal. [8]

Conditions Where Off-Label Use Is Not Supported

Idiopathic juvenile osteoporosis with expected spontaneous recovery, low bone density from eating disorders without multiple fractures, and low bone density attributable solely to delayed puberty without structural bone disease are not contexts where romosozumab has been used or described. These conditions typically respond to nutritional rehabilitation, hormonal therapy, or watchful waiting, and the risk-benefit calculus for romosozumab does not favor it.

Regulatory and Ethical Considerations

Pediatric Research Gap

The FDA's Pediatric Research Equity Act (PREA) requires sponsors to conduct pediatric studies for drugs likely to be used in children. Amgen submitted a Pediatric Study Plan for romosozumab, and NCT02875834 represents part of that plan, but the program has progressed slowly. [14] As of 2025, no supplemental new drug application (sNDA) for a pediatric indication has been filed.

The American Academy of Pediatrics section on endocrinology has noted that the pediatric bone pharmacology evidence base lags adult bone pharmacology by 10 to 15 years on average for novel agents. [15]

Institutional Review and Compassionate Use

For individual adolescent patients outside a clinical trial, prescribers seeking romosozumab can pursue two pathways. First, enrollment in an active trial (ClinicalTrials.gov currently lists NCT02875834 and successor protocols). Second, expanded access or compassionate use via FDA's individual patient expanded access pathway, which requires physician submission and FDA review within 24 to 48 hours for non-emergency cases. [5]

Insurance coverage for off-label romosozumab in minors is almost universally denied on first submission. Appeals require documented bisphosphonate failure, specialist letters, and, where available, relevant published case data. Some payers have granted coverage under step-therapy exceptions when the prescribing physician is a fellowship-trained pediatric endocrinologist.

Monitoring Protocol for Adolescents Receiving Off-Label Romosozumab

Before the First Injection

• Serum calcium, phosphate, magnesium, creatinine, and 25-OH vitamin D level.
• Correct any vitamin D deficiency to greater than 30 ng/mL before starting.
• Ensure daily calcium intake of at least 1,300 mg (adolescent RDA per Institute of Medicine) through diet and supplementation combined. [2]
• Baseline DXA (lumbar spine and total hip; adjust for height using Z-scores not T-scores in growing patients).
• Baseline bone turnover markers: serum P1NP and CTX-1.
• Cardiovascular history screening: any prior cardiac event, familial hyperlipidemia, or congenital heart disease warrants cardiology consultation before prescribing.

During 12-Month Treatment

• Serum calcium and phosphate before each monthly injection.
• Bone turnover markers at 1 month (to confirm anabolic response) and 6 months.
• DXA at 12 months (completion of approved treatment window).

After Stopping Romosozumab

Transition to an antiresorptive agent should be planned before the last romosozumab injection, not after. The choice between oral bisphosphonate, IV zoledronic acid, or denosumab depends on the underlying diagnosis, growth plate status, and, for adolescent females, reproductive counseling regarding bisphosphonate skeletal retention. Denosumab carries its own rebound risk if discontinued abruptly and is generally not the preferred follow-on agent in adolescents for that reason. [11]

What Families and Patients Should Know

Adolescents and their caregivers weighing romosozumab off-label need three clear points.

First, this is a research-stage use. The drug has not been proven safe or effective in anyone under 18 in a completed randomized trial. The case evidence is encouraging but small.

Second, the 12-month time limit is real. Romosozumab is not a long-term medication. It opens an anabolic window, and that window closes after one year regardless of outcome. What comes after romosozumab is as important a conversation as the drug itself.

Third, administration requires monthly clinic or home-nursing visits for two subcutaneous injections. Adolescents with needle anxiety, difficulty maintaining monthly schedules, or unreliable access to monitoring labs are poor candidates logistically, independent of the clinical profile.

The Osteogenesis Imperfecta Foundation maintains a patient registry and can connect families with trial-enrolled centers, which is often the safest route to access for motivated families. [12]